Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

“The data we will present at ADA highlight the growing strength of our obesity portfolio, exemplified by the robust efficacy and distinct tolerability profiles of enicepatide and petrelintide,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “The clinical insights from these studies demonstrate how our portfolio may offer more tailored, individualised treatment options for people living with obesity.”

The data presented on Roche’s obesity assets include:

Roche continues to advance its weight management pipeline rapidly, moving both enicepatide and petrelintide into Phase III development while initiating a Phase II multi-arm combination trial in mid-2026.

Roche is pleased to invite investors and analysts to participate in its virtual event on Monday, 8 June 2026, that will highlight the new data from the Phase II CT388-103 study of enicepatide, as well as from the Phase II ZUPREME-1 study of petrelintide.

Additional details on presentations at the ADA’s Scientific Sessions are included below and the full abstracts will be available in Diabetes.

About Enicepatide (CT-388)
Enicepatide is an investigational once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed for the treatment of people living with obesity and associated comorbidities including type 2 diabetes (T2D). Enicepatide was designed to have potent activity on both the GLP-1 and GIP receptors but with minimal to no beta-arrestin recruitment on either receptor. This biased signalling significantly minimises receptor internalisation and consequent desensitisation, which is expected to lead to prolonged pharmacological activity.

About Petrelintide
Petrelintide is an investigational long-acting amylin analog suitable for once-weekly subcutaneous administration that has been designed with chemical and physical stability with no fibrillation around neutral pH, allowing for co-formulation and co-administration with other peptides.¹ Amylin is produced in the pancreatic beta cells and co-secreted with insulin in response to ingested nutrients. Amylin receptor activation has been shown to reduce body weight by restoring sensitivity to the satiety hormone leptin^2,3 inducing a sense of feeling full faster.

About Obesity
Obesity is recognised as the greatest single risk factor for chronic disease globally. The condition is associated with many health challenges and more than 200 comorbidities, including type 2 diabetes, cardiovascular diseases, fatty liver, and chronic kidney disease. By 2035, over four billion people (more than half of the global population) are projected to be living with excess weight or obesity, a trend affecting nearly every country. This rise is driven by a complex mix of genetics and biology as well as behavioural, environmental and socioeconomic factors, placing an increased strain on healthcare systems due to the associated burden of comorbidities and reduced quality of life.

About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] Eriksson et al. Presentation at ObesityWeek, November 1–4, 2022, San Diego, CA. Link: https://www.zealandpharma.com/media/0gnfxg4b/zp8396-sema-coformulation-obesityweek-2022.pdf.
[2] Mathiesen et al. Eur J Endocrinol 2022;186(6):R93–R111
[3] Roth et al. Proc Natl Acad Sci U S A 2008;105(20):7257–7262

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Roche Investor Relations

Investor Relations North America

Attachment